Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment and Prevention of Hepatitis C

Hepatitis C virus is an enveloped, single stranded RNA virus, approximately 50 nm in diameter, that has been classified as a separate genus in the Flaviviridae family. Most persons infected with hepatitis C virus develop chronic infection. These chronically infected individuals have a relatively high risk of developing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. There is currently no vaccine to prevent the hepatitis C virus infection. The present invention relates to human monoclonal antibodies which exhibit immunological binding affinity for the hepatitis C virus E2 glycoprotein and are cross-reactive against different hepatitis C virus strains. These antibodies may be used in passive immunoprophylaxis for the prevention of hepatitis C virus infection and/or in passive immunotherapy for the treatment of hepatitis C.IC: NIAIDNIH Ref. No.: E-017-2001-0TAB No: TAB-203Applications: In vitro diagnostic assay for identifying patients infected with hepatitis C virus and contaminated blood samplesMethod of preventing infection using monoclonal antibodies that neutralize E2 glycoproteins from different genotypes of hepatitis C virusProvider Technology ID: 203Updated On: Jul 6, 2020Date Published: Monday, July 6, 2020Patent Application: 60/250,561PCT/US01/4522110/432,006Patent Authority: USPCTEIRUSPatent Number: 6,924,362Lead Inventor: Inventor IC: NIAIDNIAIDNIAIDLPM FIrst Name: PeterLPM Last Name:&n...

Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research